ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1235

Treatment Effect of Baricitinib on Fatigue: Mediation Analysis Results from Two Phase 3 Trials
Abstract Number: 0139

Treatment of Ankylosing Spondylitis by Primary Care Physicians and Rheumatologists in an Academic Health System: A Retrospective Study
Abstract Number: 1408

Treatment of Giant Cell Arteritis in the ARTESER Multicenter Study of 1675 Patients
Abstract Number: 1397

Treatment of Giant Cell Arteritis with Tocilizumab: A Retrospective Cohort Study of 119 Patients
Abstract Number: 1736

Treatment of Lupus Nephritis with Belimumab Is Associated with Reduction in Urinary CD23
Abstract Number: 1816

Treatment of Non-biologic-DMARD-IR PsA Patients with Upadacitinib or Adalimumab Results in the Modulation of Distinct Functional Pathways: Proteomics Analysis of a Phase 3 Study
Abstract Number: 0207

Treatment of Ocular Sarcoidosis: Study of 65 Patients of a Series of 384 Patients from a Single University Hospital
Abstract Number: 1263

Treatment of Pediatric Lupus Is Associated with Significant Re-Organization of B Cell Chromatin
Abstract Number: 1749

Treatment Patterns in Latin American Patients with Lupus Nephritis over a 20-year Period
Abstract Number: 0463

Treatment Persistence Among Medicare Beneficiaries with Seropositive Rheumatoid Arthritis Initiating Biologic or Targeted Synthetic DMARDs
Abstract Number: 1339

Treatment Persistence Was Similar at 3 Years in Patients with Psoriatic Arthritis Treated with Ustekinumab (STELARA®) or a Tumor Necrosis Factor Inhibitor in a Prospective Real-World Study
Abstract Number: 0550

Treatment Regimens and Outcomes in Systemic Sclerosis-associated Pulmonary Arterial Hypertension
Abstract Number: 0795

Treatment Response and Several Patient-reported Outcomes Are Early Determinants of Future Self-efficacy in Patients with Rheumatoid Arthritis
Abstract Number: 0138

Treatment with Adalimumab in Patients with Chronic Inflammatory Rheumatic Diseases: A Study of Treatment Trajectories on a Patient Level in Clinical Practice
Abstract Number: 1465

Trends in Adverse Pregnancy Outcomes Among Women with Systemic Sclerosis in the United States

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].